Intercept Pharmaceuticals, Inc. announced today new analyses of - TopicsExpress



          

Intercept Pharmaceuticals, Inc. announced today new analyses of data from clinical trials on obeticholic acid (OCA) in patients with primary biliary cirrhosis (PBC). Six posters, including posters with new analyses of data from POISE - the first Phase 3 trial in PBC in two decades - are being presented at todays poster session at the American Association for the Study of Liver Disease (AASLD) Annual Meeting. مندوب تسجيل الدواء فى مصر
Posted on: Sun, 09 Nov 2014 20:41:24 +0000

Trending Topics



Recently Viewed Topics




© 2015